Skip to main content
Top
Published in: Familial Cancer 1/2018

01-01-2018 | Original Article

A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting

Authors: Michael P. O’Leary, Bryan S. Goldner, Sridevi Abboy, Philip D. Mercado, Hong Yoon Plurad

Published in: Familial Cancer | Issue 1/2018

Login to get access

Abstract

The introduction of screening for multiple high and moderate risk mutations in genes has resulted in a complex approach to patient care involving multiple disciplines. We sought to describe the feasibility of a single visit multidisciplinary approach to the management of patients with an identified high/moderate risk gene mutation. Patients who presented to our community hospital over a 1-year period who were found to have a high/moderate risk genetic mutation on a screening panel were referred to the High Risk Genetic Clinic. Thirty-five patients were included. The majority were female [34 (97.1%)], Hispanic [22 (62.9%)], with a family history of cancer [21 (60%)]. Mean age was 40.3 years. Most of the participants had a BRCA1 gene mutation [10 (28.6%)]. Patients were seen at the High Risk Genetic Clinic within a mean of 41.9 days from the day of genetic mutation diagnosis. Four patients did not show and were significantly younger (19.3 vs. 39.6 years, p = 0.014). In this community setting, we provided coordinated care within multiple disciplines related to a genetic mutation in a single clinic visit. Increased efforts at coordinating early care should be directed towards patients diagnosed at a younger age.
Literature
2.
go back to reference Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31:1267–1270CrossRefPubMed Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31:1267–1270CrossRefPubMed
3.
go back to reference Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345CrossRefPubMed Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345CrossRefPubMed
6.
go back to reference Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N (2011) PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 10:225–231CrossRefPubMed Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N (2011) PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 10:225–231CrossRefPubMed
7.
go back to reference Verna EC, Hwang C, Stevens PD et al (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028–5037CrossRefPubMed Verna EC, Hwang C, Stevens PD et al (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028–5037CrossRefPubMed
9.
go back to reference NCCN Practical Guidelines in Oncology (NCCN Guidelines) (2017) Genetic/familial high-risk assessment: breast and ovarian. Version 2.2017. http://www.nccn.org. Accessed Feb 2017 NCCN Practical Guidelines in Oncology (NCCN Guidelines) (2017) Genetic/familial high-risk assessment: breast and ovarian. Version 2.2017. http://​www.​nccn.​org. Accessed Feb 2017
Metadata
Title
A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting
Authors
Michael P. O’Leary
Bryan S. Goldner
Sridevi Abboy
Philip D. Mercado
Hong Yoon Plurad
Publication date
01-01-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0010-1

Other articles of this Issue 1/2018

Familial Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine